Gilead Sciences Inc. (GILD)

70.55
NASDAQ : Health Technology
Prev Close 70.55
Day Low/High 0.00 / 0.00
52 Wk Low/High 64.27 / 89.54
Avg Volume 6.61M
Exchange NASDAQ
Shares Outstanding 1.29B
Market Cap 91.19B
EPS 3.50
P/E Ratio 56.74
Div & Yield 2.28 (3.16%)

Latest News

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Announces Positive Phase 2 Results For GS-9674 In Primary Sclerosing Cholangitis (PSC) At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program For Advanced Fibrosis At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the company's clinical development program for advanced fibrosis due to nonalcoholic steatohepatitis (NASH).

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead Sciences Is Sporting a Bearish Set of Charts for Investors

Gilead has been trying to turn things around but few see that turn coming anytime soon.

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead To Present Latest Scientific Research In Hematologic Malignancies And Solid Tumors At ASH 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its oncology and cell therapy research programs will be presented at the 60 th American Society of Hematology (ASH) Annual Meeting & Exposition, in San Diego from December 1 - 4, 2018.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc.

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...

Be Ready to Ride the Dividend on Gilead Sciences

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

Gilead Sciences Announces Fourth Quarter 2018 Dividend

Gilead Sciences Announces Fourth Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Third Quarter 2018 Financial Results

Gilead Sciences Announces Third Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended September 30, 2018.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Is the Fed on Course?: Cramer's 'Mad Money' Recap (Wednesday 10/17/18)

Is the Fed on Course?: Cramer's 'Mad Money' Recap (Wednesday 10/17/18)

Jim Cramer evaluates the Federal Reserve's interest-rate moves and says it's right to stay focused on any form of inflation.

Gilead Sciences, KeyCorp, Ventas: 'Mad Money' Lightning Round

Gilead Sciences, KeyCorp, Ventas: 'Mad Money' Lightning Round

Jim Cramer weighs in on Gilead Sciences, KeyCorp, Ventas, Weight Watchers, Del Taco Restaurants, Hanesbrands, Kraft Heinz and more.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

Jim Cramer takes a look at General Electric, Chevron, Manitowoc, Gilead Sciences, Encore Capital Group, Tower Semiconductor, Camping World, Kinder Morgan and more.

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

Jim Cramer says sustained, revolutionary innovation creates new demand where it didn't exist before.

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis Both Published In The Lancet

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis...

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis To Be Presented At 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely...

Gilead Sciences To Release Third Quarter 2018 Financial Results On Thursday, October 25, 2018

Gilead Sciences To Release Third Quarter 2018 Financial Results On Thursday, October 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes.

Gilead To Present Wide-Ranging New Data On Treatment And Diagnosis Of Liver Diseases At The Liver Meeting® 2018

Gilead To Present Wide-Ranging New Data On Treatment And Diagnosis Of Liver Diseases At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the company's liver disease research and development programs in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), hepatitis B virus (HBV) infection and hepatitis...

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1489) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...

Hong Kong Department Of Health Approves Biktarvy(R) (bictegravir, Emtricitabine, Tenofovir Alafenamide)

Hong Kong Department Of Health Approves Biktarvy(R) (bictegravir, Emtricitabine, Tenofovir Alafenamide)

In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks HONG KONG, Oct.

Kite And HiFiBiO Therapeutics Announce A Research Collaboration To Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) For The Treatment Of Cancer

Kite And HiFiBiO Therapeutics Announce A Research Collaboration To Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) For The Treatment Of Cancer

Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration...

Gilead Has Strengthened So Go Long and Add to Longs

Gilead Has Strengthened So Go Long and Add to Longs

Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Total SA, Bluebird Bio, U.S. Silica Holdings, Nucor, International Paper, Nokia, Alibaba.

Gilead Subsidiary To Launch Authorized Generics Of Epclusa® (Sofosbuvir/Velpatasvir) And Harvoni® (Ledipasvir/Sofosbuvir) For The Treatment Of Chronic Hepatitis C

Gilead Subsidiary To Launch Authorized Generics Of Epclusa® (Sofosbuvir/Velpatasvir) And Harvoni® (Ledipasvir/Sofosbuvir) For The Treatment Of Chronic Hepatitis C

Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni ® (ledipasvir 90mg/sofosbuvir 400mg), Gilead's leading treatments for chronic hepatitis C virus...

TheStreet Quant Rating: C+ (Hold)